Polyplus Completes Acquisition of Xpress Biologics
Polyplus, a solution provider for manufacturing of Advanced Therapeutic Medicinal Products from research to commercial grade, has announced the completed acquisition of Xpress Biologics, a Belgian contract development and manufacturing organization (CDMO) specialized in the production of plasmid DNA and protein using microbial expression systems.
The acquisition will strategically expand the Polyplus plasmid DNA engineering technology and services portfolio. Additionally, it will strengthen Polyplus’ leading position focused on improving gene-therapy viral vector upstream process economics and quality.
Xpress Biologics contract development and manufacturing services will continue to be offered for Research, GLP, High Quality and GMP grade proteins and plasmids DNA for therapeutic, vaccine and diagnostic applications including mRNA and viral vector based advanced therapies, while being leveraged for large-scale production of Polyplus proprietary plasmid DNA. The proprietary plasmid DNA constructs engineered by Polyplus are developed to increase AAV production yields and quality in conjunction with innovative transfection offers.
About Xpress Biologics
Xpress Biologics is a Belgian contract development and manufacturing organization (CDMO) specialized in the production of plasmid DNA and protein using bacteria and yeast expression systems. Core applications for the technology and services include human and veterinary vaccines and biotherapeutics, as well as diagnostics.
Polyplus is an upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services including bioproduction industry standard, PEIpro®.